文献速递角膜与眼表疾病

角膜异种移植:现状与展望

Corneal xenotransplantation: Where are we standing?
PubMed 文献 · Prog Retin Eye Res · 2020-08-02

综述指出角膜供体短缺推动异种移植探索,基因编辑猪与CRISPR-Cas9及先进免疫抑制剂使猪角膜异种移植成为可能。眼被视为免疫豁免部位,非人灵长类研究显示猪异种移植物在角膜移植中可长期存活。文章综述免疫豁免、异种排斥机制、免疫抑制方案、临床前数据与监管框架,并讨论伦理与异种感染风险。

要点

  • 猪角膜异种移植因眼免疫豁免及基因编辑猪进展而具临床可行性。
  • 非人灵长类研究显示猪异种移植物在角膜移植中可长期存活。
  • 伦理争议、公众担忧与异种感染风险是临床转化的主要障碍。

核心结论

  • 基因编辑猪、CRISPR-Cas9与先进免疫抑制剂使角膜异种移植进入人试试验可行阶段。
  • 眼免疫豁免与非人灵长类长期存活数据支持猪角膜异种移植的适用性。

研究设计与样本

  • 本文为综述,检索并汇总角膜异种移植相关文献,未报告系统检索范围与样本量。

主要发现

  • 非人灵长类研究显示猪异种移植物在角膜移植中可长期存活。
  • 综述涵盖异种排斥机制、免疫抑制方案、临床前疗效与安全性数据及临床试验监管框架。
  • 脱细胞猪角膜(DPC)的法律定义介于医疗器械与异种移植物之间,其临床前与临床试验数据被纳入。

临床怎么用

  • 临床转化需关注异种排斥机制与免疫抑制方案,并遵循临床试验监管框架。
  • 应用脱细胞猪角膜时需考虑其介于医疗器械与异种移植物之间的法律定义。

局限性

  • 伦理困境、公众对异种移植的担忧及异种感染可能风险阻碍其成为常规实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The search for alternatives to allotransplants is driven by the shortage of corneal donors and is demanding because of the limitations of the alternatives. Indeed, current progress in genetically engineered (GE) pigs, the introduction of gene-editing technology by clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, and advanced immunosuppressants have made xenotransplantation a possible option for a human trial. Porcine corneal xenotransplantation is considered applicable because the eye is regarded as an immune-privileged site. Furthermore, recent non-human primate studies have shown long-term survival of porcine xenotransplants in keratoplasty. Herein, corneal immune privilege is briefly introduced, and xenogeneic reactions are compared with allogeneic reactions in corneal transplantation. This review describes the current knowledge on special issues of xenotransplantation, xenogeneic rejection mechanisms, current immunosuppressive regimens of corneal xenotransplantation, preclinical efficacy and safety data of corneal xenotransplantation, and updates of the regulatory framework to conduct a clinical trial on corneal xenotransplantation. We also discuss barriers that might prevent xenotransplantation from becoming common practice, such as ethical dilemmas, public concerns on xenotransplantation, and the possible risk of xenozoonosis. Given that the legal definition of decellularized porcine cornea (DPC) lies somewhere between a medical device and a xenotransplant, the preclinical efficacy and clinical trial data using DPC are included. The review finally provides perspectives on the current standpoint of corneal xenotransplantation in the fields of regenerative medicine.

来源:Prog Retin Eye Res,查看原文。版权归原作者所有。

引用

  1. Yoon CH, Choi HJ, Kim MK, et al. Corneal xenotransplantation: Where are we standing? Prog Retin Eye Res. 2020. PMID: 32755676. doi:10.1016/j.preteyeres.2020.100876

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。